Portugal

MOST INNOVATIVE BIOTECHNOLOGY COMPANY

SICGEN Antibodies

www.sicgen.masterinsoft.com | +351 919 145 219 | information@sicgen.pt

Located in the Coimbra region, SICGEN Antibodies is a biotechnology company that develops, manufactures, and markets polyclonal antibodies for cell biology research. Founded in 2009, the company aims to become a global producer of high-quality polyclonal antibodies and related products which can be effectively used in important life science research. Its production unit has been seamlessly integrated into one of Portugal's most rural areas, and possesses the cutting-edge technology and talented staff required to meet demand in the market place. Led by its founder, Portuguese scientist Dr José Ramalho, SICGEN currently focuses on antibodies such as Western Blotting, Immunofluorescence, and Immunocytochemistry, and its range contains more than 300 products, with more on the horizon.

SICGEN's collection of polyclonal antibodies are frequently used by leading national and international institutions, such as universities, research institutes, pharmaceutical manufacturers, and biotechnology distributors, with many clients based in North America, Europe, and the Far East. The company is able to create such high-quality products at competitive prices as it develops its antibodies safely within goats. SICGEN uses recombinant proteins produced in the laboratory to attain immunisation and affinity purification – as opposed to using synthetic peptides, which offer fewer benefits. The company has been able to find gaps in the marketplace where the supply of high-quality antibodies is low, and has since focused its production process in those areas – gaining a competitive edge.

> SICGEN AIMS TO BECOME A GLOBAL PRODUCER OF HIGH-QUALITY POLYCLONAL ANTIBODIES AND RELATED PRODUCTS.

DR JOSÉ RAMALHO

The judging panel was particularly impressed by the sustainable practices that the company has implemented over the last 12 months. SICGEN Antibodies is putting an enormous focus on optimising its use of energy and water in its research and production processes, and has reduced its consumption of raw materials and heightened its level of recycling in recent times. Furthermore, the company has installed solar panels for electricity generation at its production facility, and in turn, has reduced its carbon emissions. SICGEN's innovative operation is ready to embrace the future as vitro technologies come into the fore, and these advancements will see the company embrace non-animal-based approaches toward antibody production.